Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

BMS Adds New NASH Drug to its Portfolio

By Ryan Bushey | November 10, 2016

Bristol-Myers Squibb has acquired the rights to an early-stage drug candidate targeting liver fibrosis that occurs as a result of nonalcoholic steatohepatitis (NASH).

The biotech company will pay $100 million upfront to Japan’s Nitto Denko who developed this drug.

Nitto will be able to receive a number of clinical and regulatory milestone payments and royalties under the deal, reported Reuters. BMS will also have the ability to option exclusive licensing rights for other drugs Nitto is working on for potentially treating lung fibrosis and similar conditions.

The drug BMS is incorporating into its portfolio is a siRNA inhibitor designed to inhibit heat shock protein 47, explained Endpoints News. The hope is that the drug attacking this protein may impede the production of collagen that plays a part in the formation of fibrosis and NASH.

Investigators are currently running a Phase 1b study to track how this drug could perform that action on patients over the course of 5 weeks.

Mergers and acquisition deals have been particularly active in the NASH space over the past few months.

Allergan acquired a slew of companies specializing in this type of drug development. Gilead reported promising data for a NASH candidate that lead to mixed but well tolerated results in improving liver fibrosis as well.

An analysis published by Thompson Reuters in February noted this development area could yield over $1 billion in sales for companies who create a potent drug.  


Filed Under: Drug Discovery

 

Related Articles Read More >

Sanders, King target DTC pharma ads but the industry worries more about threats to its $2B R&D model
Zoliflodacin wins FDA nod for treatment of gonorrhea
FDA approved ENFLONSIA for the prevention of RSV in Infants
First clinical study results of Dupixent for atopic dermatitis in patients with darker skin tones 
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE